CD19 CAR-T therapy has been widely used in the treatment of B cell lymphoma and leukemia; however, a subset of patients eventually relapses because of antigen loss or downregulation on malignant cells (16). This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.